Skip to content

Citius Oncology, Inc. CTOR Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Merck & Co. logo
Merck & Co.MRK
-$460.25M+20.9%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$21.04M-1,035%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$3.14M+124%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$2.33M+91.4%
Gilead Sciences logo
Gilead SciencesGILD
-$702M-188%

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s change in accrued liabilities?
Citius Oncology, Inc. (CTOR) reported change in accrued liabilities of $19.54M in Q1 2026.
How has Citius Oncology, Inc.'s change in accrued liabilities changed year-over-year?
Citius Oncology, Inc.'s change in accrued liabilities increased by 683.6% year-over-year, from $2.49M to $19.54M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.